Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer and autoimmune diseases. Leveraging the expertise of former Kite Pharma executives, Allogene aims to revolutionize cancer treatment with innovative off-the-shelf CAR T solutions. These therapies, derived from healthy donor cells, provide a scalable and readily available option, eliminating the lengthy and complex process of personalized cell therapy.
The company's portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy in phase 1 development for acute lymphoblastic leukemia (ALL). Notable core programs target various malignancies such as lymphoma, leukemia, solid tumors, and autoimmune diseases. Among its leading investigational products is cemacabtagene ansegedleucel (cema-cel), currently undergoing pivotal phase 2 ALPHA3 trials for large B-cell lymphoma (LBCL) and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL). ALLO-316, aimed at renal cell carcinoma (RCC), and ALLO-329, targeting autoimmune diseases with Dagger® technology, further strengthen Allogene's robust pipeline.
Allogene collaborates with leading biotech firms like Foresight Diagnostics and Arbor Biotechnologies to enhance its clinical development capabilities. Recent achievements include strategic partnerships and a $15 million grant from the California Institute for Regenerative Medicine (CIRM) supporting the development of ALLO-316. Financially, Allogene reported a strong cash runway extending into 2026, with latest funding rounds ensuring continued support for its R&D initiatives.
Stay informed on Allogene's progress as it drives the future of allogeneic CAR T therapy, providing broader patient access and more efficient cancer treatment options.
Allogene Therapeutics (NASDAQ: ALLO) announced promising results from the Phase 1 UNIVERSAL trial of ALLO-715, the first allogeneic anti-BCMA CAR T therapy for multiple myeloma demonstrating substantial safety and efficacy. The trial achieved a 71% overall response rate (ORR), with 46% achieving a very good partial response (VGPR) or better. Notably, no cases of graft-versus-host disease were reported. The study enables rapid therapy initiation, with a median treatment start time of five days. ALLO-715 received RMAT designation from the FDA, reinforcing its potential in treating relapsed/refractory myeloma.
Allogene Therapeutics reported promising results from its Phase 1 trials (ALPHA and ALPHA2) of AlloCAR T therapy for treating large B-cell lymphoma and follicular lymphoma. The therapy exhibited a 44% complete response rate in large B-cell lymphoma patients, with no relapses observed in those achieving complete response at six months. The regimen was well tolerated, showing low adverse event rates. Allogene plans to initiate a pivotal Phase 2 trial in relapsed/refractory large B-cell lymphoma, contingent upon discussions with the FDA, aiming for accelerated patient treatment timelines.
Allogene Therapeutics (Nasdaq: ALLO) announced a conference call scheduled for December 13, 2021, at 1:30 PM PT/4:30 PM ET. The call will cover data from the ALPHA, ALPHA2, and UNIVERSAL Phase 1 trials concerning their AlloCAR T™ therapies for treating relapsed/refractory non-Hodgkin lymphoma and multiple myeloma. The live call can be accessed via phone or webcast, with a replay available for 30 days on their website. Allogene specializes in developing innovative, scalable cell therapies for cancer.
Allogene Therapeutics (Nasdaq: ALLO), a biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer, announced its participation in five virtual investor conferences. These include Cowen's IO Next Summit on November 15, Stifel's Healthcare Conference on November 16, and others through December 6. Webcasts will be available on Allogene's website, providing investors with insights into the company's innovative therapies and future developments.
Allogene Therapeutics (ALLO) recently announced updates surrounding its AlloCAR T™ clinical trials, including presentations at the upcoming American Society of Hematology annual meeting.
The ALPHA2 trial showcased the benefits of consolidation dosing with ALLO-501A in relapsed/refractory large B-cell lymphoma. The company reported a third-quarter net loss of $78.2 million and ended the quarter with $862 million in cash and equivalents. Ongoing discussions with the FDA aim to resolve a clinical hold on its trials following a chromosomal abnormality report.
Allogene Therapeutics (ALLO) announced the selection of three abstracts for oral and poster presentations at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 13, 2021. The presentations will showcase updated data from the ALPHA2 study of ALLO-501A in large B-cell lymphoma, the ALPHA study of ALLO-501 in non-Hodgkin lymphoma, and the UNIVERSAL study of ALLO-715 in multiple myeloma. These findings highlight the potential of AlloCAR T therapies in treating relapsed/refractory blood cancers, with encouraging efficacy and manageable safety profiles reported.
Allogene Therapeutics (ALLO) will release its third quarter 2021 financial results on November 4, 2021, after market close. A conference call and webcast will follow at 2 PM PT/5 PM ET. Allogene, based in South San Francisco, focuses on developing allogeneic CAR T (AlloCAR T™) therapies for cancer, aiming to provide readily available cell therapy to patients. Shareholders can access the live webcast on the company's website, with a replay available for 30 days.
Allogene Therapeutics (Nasdaq: ALLO) announced that the FDA has placed a clinical hold on its AlloCAR T trials following the detection of a chromosomal abnormality in a patient treated with ALLO-501A. The patient showed a partial response but developed progressive pancytopenia and aplastic anemia, leading to an investigation into the abnormality's clinical significance. The company believes data from the ALPHA trials support a favorable profile for ALLO-501A, and it is working closely with the FDA to address any potential clinical implications.
Allogene Therapeutics (Nasdaq: ALLO) announced the addition of Dr. Jae Park, a leading expert in cell therapies, to its Scientific Advisory Board. Dr. Park, associated with Memorial Sloan Kettering Cancer Center, has extensive experience in CAR T therapies and is the principal investigator for multiple clinical trials. This appointment aims to enhance Allogene's research capabilities in developing allogeneic CAR T (AlloCAR T™) therapies for various cancers. The company seeks to leverage Dr. Park's expertise to advance its initiatives in treating blood cancers and solid tumors.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company, announced its participation in two virtual investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 4:00 AM PT. The second is the BofA Global Research Global Healthcare Conference on September 16, 2021, at 10:25 AM PT. Webcasts will be available on their website following the events. Allogene specializes in allogeneic CAR T therapies aimed at making cell therapy more accessible to patients worldwide.
FAQ
What is the current stock price of Allogene Therapeutics (ALLO)?
What is the market cap of Allogene Therapeutics (ALLO)?
What is Allogene Therapeutics, Inc.?
What are Allogene's core products?
What is unique about Allogene's therapies?
Who are Allogene's key partners?
In which clinical trials is cema-cel involved?
What recent financial achievement did Allogene secure?
How does Allogene's financial outlook appear?
What is the focus of Allogene's ALLO-316 trial?
What is the Dagger® technology used in ALLO-329?
What is the goal of Allogene's therapies?
